文献速递慢性静脉疾病静脉血栓栓塞

专用静脉支架治疗慢性髂股静脉梗阻的长期结局

Long-term outcome of dedicated venous stents in management of chronic iliofemoral obstruction.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2021-05-18

单中心回顾性分析58例良性病因慢性髂股静脉梗阻患者,使用Zilver Vena支架行再通术。中位随访60个月,5年一期通畅率60.3%,辅助一期通畅率65.5%,二期通畅率81%,静脉 disability 评分从基线3显著降至1(P < .001),无支架断裂、移位或结构变形。

要点

  • 专用静脉支架治疗血栓后综合征相关髂股静脉梗阻5年二期通畅率达81%。
  • 5年随访静脉残疾评分从3显著降至1(P < .001),临床改善明显。
  • 无支架断裂、移位或结构变形发生。

核心结论

  • 专用静脉支架治疗闭塞性血栓后综合征的髂股静脉病变是极佳选择,1年和5年通畅率良好,临床改善显著且并发症少。

研究设计与样本

  • 单中心回顾性分析2013年1月至2020年10月58例有症状良性下肢慢性静脉功能不全患者的前瞻性收集数据,均置入Zilver Vena支架。
  • 排除急性深静脉血栓干预后需支架、恶性肿瘤或血管畸形所致CVI、既往同侧静脉干预、非梗阻性反流性CVI者。
  • 基线用CEAP分级、静脉残疾评分和Villalta评分进行临床分类,随访1、3、6、12个月及每年至5年,评估支架通畅性。

主要发现

  • 58例中男31例、女27例,年龄25-60岁(平均43.84岁),均为血栓后综合征,平均Villalta评分16.8(范围10-31)。
  • 中位随访60个月,静脉残疾评分中位数从基线3显著降至5年随访时1(P < .001)。
  • 12个月一期、辅助一期和二期通畅率分别为91.4%、96.6%和98.3%。
  • 5年随访时一期通畅率60.3%,辅助一期通畅率65.5%,二期通畅率81%。
  • 无支架断裂、移位或结构变形发生。

关键数值与推荐

  • 12个月一期通畅率91.4%,辅助一期通畅率96.6%,二期通畅率98.3%。
  • 5年一期通畅率60.3%,辅助一期通畅率65.5%,二期通畅率81%。
  • 静脉残疾评分中位数从基线3降至5年随访1(P < .001)。

临床怎么用

  • 对良性病因闭塞性髂股静脉慢性静脉功能不全患者,可考虑使用专用静脉支架(Zilver Vena)行再通术。
  • 术后需长期随访监测支架通畅性,尤其5年时一期通畅率降至60.3%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the long-term outcomes in patients with occlusive Iliofemoral chronic venous insufficiency (CVI) of benign etiology treated by dedicated venous stents (Zilver Vena stents; Cook, Bloomington, Ind) placed at a single center. METHODS: We performed retrospective analysis of prospectively collected data from 58 patients with symptomatic benign lower limb CVI during the period from January 2013 to October 2020. Patients underwent recanalization using Zilver Vena stents at Ain Shams University hospitals. We excluded patients requiring stenting after intervention for acute deep venous thrombosis, CVI due to malignancy or vascular malformations, previous ipsilateral venous interventions, or CVI due to nonobstructive pathology (reflux). Patients were clinically classified at enrollment by the clinical, etiology, anatomy, pathology class, venous disability score, and Villalta score. Primary, assisted primary, and secondary stent patency were assessed. Patients were followed clinically and by duplex, at 1, 3, 6, 12 months and annually for 5 years. RESULTS: There were 31 males and 27 females, with ages ranging between 25 and 60 years (mean, 43.84 years). All patients had post-thrombotic syndrome with a mean Villalta score of 16.8 (range, 10-31). Patients were treated with dedicated venous stents and had a median follow-up of 60 months. The median venous disability score was 3 at the start of the study with a significant decrease to 1 at 5-year follow-up (P < .001). Twelve-month primary patency, assisted primary patency, and secondary patency were 91.4%, 96.6%, and 98.3%, respectively. At the 5-year follow-up, primary patency was 60.3%, assisted primary patency 65.5%, and secondary patency 81%. There were no instances of stent fracture, migration, or structural deformities. CONCLUSIONS: Treating iliofemoral venous occlusive disease with a dedicated venous stent is an excellent choice for patients with occlusive post-thrombotic syndrome. The technique has good 1-year and 5-year patency and is associated with significant clinical improvement and few complications.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Salem AM, AbdelAzeem AboElNeel H, Fakhr ME, et al. Long-term outcome of dedicated venous stents in management of chronic iliofemoral obstruction. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34020109. doi:10.1016/j.jvsv.2021.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。